Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CA$ 7.35
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
InnoCan Pharma Corporation, a pharmaceutical company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Poland, France, and internationally. The company engages in the research and development of COVID-19 and other condition treatment by using CBD loaded exosomes; and CBD loaded liposomes. Its product...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is overvalued on EV/EBITDA.
Data is available to registered users only
Buy
Sell